Embla Medical hf./DKr EMBLA
1D1W1MYTD1Y5YMAX
About Embla Medical hf.
Embla Medical hf., headquartered in Reykjavik, Iceland, specializes in non-invasive orthopedic products, focusing on prosthetics, neuro orthotics, bracing, and supports. The company operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. Its product portfolio includes mechanical and bionic prosthetic devices, bracing solutions for various body parts, and patient care services for individuals with limb loss or musculoskeletal conditions. Originally founded as Össur hf. in 1971, the company rebranded to Embla Medical hf. in April 2024 to reflect its expanded scope and unified purpose. Embla Medical serves a global market, with operations across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's strategic positioning is strengthened by its diverse brand portfolio, including Össur, Fior & Gentz, College Park, and ForMotion, enabling it to offer comprehensive mobility solutions worldwide.
- Ticker
- DKr EMBLA
- Sector
- Health
- Primary listing
- CSE
- Employees
- 4,500
- Headquarters
- Reykjavik, Iceland
- Website
- www.emblamedical.com
EMBLA Metrics
BasicAdvanced
kr 13B
21.66
kr 1.40
0.46
-
Price and volume
Market cap
kr 13B
Beta
0.46
52-week high
kr 37.90
52-week low
kr 25.00
Average daily volume
68K
Financial strength
Current ratio
1.252
Quick ratio
0.672
Long term debt to equity
37.979
Total debt to equity
57.663
Interest coverage (TTM)
6.83%
Profitability
EBITDA (TTM)
1,012.07
Gross margin (TTM)
62.31%
Net profit margin (TTM)
9.54%
Operating margin (TTM)
13.59%
Effective tax rate (TTM)
22.61%
Revenue per employee (TTM)
kr 1,410,350
Management effectiveness
Return on assets (TTM)
4.93%
Return on equity (TTM)
10.71%
Valuation
Price to earnings (TTM)
21.661
Price to revenue (TTM)
2.067
Price to book
13.95
Price to tangible book (TTM)
-2,124.29
Price to free cash flow (TTM)
17.592
Free cash flow yield (TTM)
5.68%
Free cash flow per share (TTM)
1.728
Growth
Revenue change (TTM)
12.70%
Earnings per share change (TTM)
27.19%
3-year revenue growth (CAGR)
9.48%
10-year revenue growth (CAGR)
7.12%
3-year earnings per share growth (CAGR)
26.69%
10-year earnings per share growth (CAGR)
6.83%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.